Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BLACK DIAMOND THERAPEUTICS, INC.

(BDTX)
  Report
Delayed Quote. Delayed Nasdaq - 01/27 04:00:01 pm
3.58 USD   -9.37%
01/11Health Care Stocks Advancing Late in Tuesday's Session
MT
01/11Health Care Stocks Lagging Broader Tuesday Markets
MT
01/11Wall Street Wavers Pre-Bell Ahead of Powell Speech
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
3.84(c) 3.95(c) 3.99(c) 3.95(c) 3.58 Last
258 760 334 629 152 421 240 090 270 958 Volume
-3.27% +2.86% +1.01% -1.00% -9.37% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -136 M - -
Net cash position 2021 210 M - -
P/E ratio 2021 -0,95x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -155 M - -
Net cash position 2022 62,0 M - -
P/E ratio 2022 -0,90x
Yield 2022 -
Capitalization 130 M 130 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 69
Free-Float -
More Financials
Company
Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company is focused on the discovery and development of small molecule, MasterKey therapies. The CompanyÔÇÖs technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead... 
More about the company
Ratings of Black Diamond Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about BLACK DIAMOND THERAPEUTICS, INC.
01/11Health Care Stocks Advancing Late in Tuesday's Session
MT
01/11Health Care Stocks Lagging Broader Tuesday Markets
MT
01/11Wall Street Wavers Pre-Bell Ahead of Powell Speech
MT
01/11Black Diamond Shares Rally Premarket on FDA Green Light for Study
DJ
01/11Black Diamond Therapeutics Says FDA Clears IND Application for Brain-Penetrant EGFR Inh..
MT
01/11Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A ..
AQ
01/11Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, a ..
CI
01/10BLACK DIAMOND THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
01/10Black Diamond Therapeutics, Inc. Announces US Food and Drug Administration Allows its I..
CI
01/10BLACK DIAMOND THERAPEUTICS : Announces Strategic Priorities and Expected Milestones for 20..
PU
01/10BLACK DIAMOND THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
01/10Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2..
AQ
01/05Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Confere..
AQ
2021BLACK DIAMOND THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Black Diamond Therapeutics, Inc. Appoints Fang Ni, Pharm. D as Principal Financial Offi..
CI
More news
News in other languages on BLACK DIAMOND THERAPEUTICS, INC.
01/11Les actions du secteur de la santé progressent en fin de séance mardi
01/11Les actions du secteur de la santé à la traîne des marchés plus larges mardi
01/11Black Diamond Therapeutics déclare que la FDA approuve la demande d'autorisation de mis..
01/11Black Diamond Therapeutics annonce l'autorisation par la FDA de la demande de DNR pour ..
01/10Black Diamond Therapeutics, Inc. annonce que la Food and Drug Administration des États-..
More news
Analyst Recommendations on BLACK DIAMOND THERAPEUTICS, INC.
More recommendations
Chart BLACK DIAMOND THERAPEUTICS, INC.
Duration : Period :
Black Diamond Therapeutics, Inc. Technical Analysis Chart | BDTX | US09203E1055 | MarketScreener
Technical analysis trends BLACK DIAMOND THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,58 $
Average target price 27,83 $
Spread / Average Target 677%
EPS Revisions
Managers and Directors
David M. Epstein President, Chief Executive Officer & Director
Fang Ni Chief Financial & Business Officer
Robert Alexander Ingram Chairman
Elizabeth Buck CSO, EVP-Discovery & Translational Sciences
Karsten Witt Chief Medical Officer & VP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
BLACK DIAMOND THERAPEUTICS, INC.-25.89%143
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.95%47 873
BIONTECH SE-37.66%38 812